期刊文献+

革兰氏阴性益生菌大肠杆菌Nissle 1917益生机理及其在仔猪方面的应用 被引量:2

Probiotic Mechanism of Gram Negative Probiotics E. coli Nissle 1917 and Its Application in Piglets Raising
下载PDF
导出
摘要 革兰氏阴性菌大肠杆菌(E.coli)Nissle 1917(EcN)是非乳酸益生菌中研究最多的益生菌。EcN血清型为O6∶K5∶H1,具有独特的基因组、半粗糙O6-脂多糖(LPS)表型、K5型荚膜、3种不同的菌毛(F1A、F1C和卷曲菌毛)。EcN具有小菌素和铁摄取系统等特殊适应性因子,在与其他微生物竞争中起关键作用。EcN能长期稳定定植于肠道,与肠上皮细胞相互作用,发挥免疫调节生物学功能。本文就EcN的特征、定植机制、免疫调节机理和在仔猪方面应用的研究现状进行综述,以期为益生菌EcN和其他益生革兰氏阴性杆菌在动物方面研究和应用提供参考。 A gram-negative strain E. coli Nissle 1917 (EcN) is the most researched probiotic except lactic acid bacteria. EcN, serotyping of O6:K5:H1, has special genome, presents semi-rough O6-1ipopolysaccharide (LPS) phenotype, K5 type and 5 different fimbriae ( FIA, F1C and a kind of curli fimbriae capsule). The iron uptake system and the microcin of EcN, acting as their "fitness factor", are essential to antagonizing other bacteria. EcN has long-term steady colonization in the gut, interact with intestinal epithelial cells and develop immunomodulation biological function. This paper reviewed the futures, colonization mechanism, immuno- modulation mechanism of EcN and its application in piglets raising, which will provide reference for further study on EcN and other probiotic gram-negative bacteria in animal intestine.
出处 《动物营养学报》 CAS CSCD 北大核心 2014年第9期2476-2482,共7页 CHINESE JOURNAL OF ANIMAL NUTRITION
基金 国家973重点基础研究发展计划项目(2013CB127303) 中央高校基本业务费专项资金(XDJK2014B028) 重庆市自然科学基金(cstc2012jjA80001) 国家循环农业项目(2012BAD14B18)
关键词 ECN 定植 免疫调节 适应因子 肠道 EcN colonization immunomodulation fitness factors intestine
  • 相关文献

参考文献2

二级参考文献52

  • 1王玮,孙梅.胃肠黏膜抗损伤和修复新进展[J].世界华人消化杂志,2005,13(19):2355-2359. 被引量:17
  • 2[1]MacDonald TT,Pettersson S.Bacterial regulation of intestinal immune responses.Inflamm Bowel Dis 2000; 6:116-122
  • 3[2]Sartor RB.Review article:Role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis.Aliment Pharmacol Ther 1997; 11 Suppl 3:17-22; discussion 22-23
  • 4[3]Campieri M,Gionchetti P.Bacteria as the cause of ulcerative colitis.Gut 2001; 48:132-135
  • 5[4]Janowitz HD,Croen EC,Sachar DB.The role of the fecal stream in Crohn's disease:an historical and analytic review.Inflamm Bowel Dis 1998; 4:29-39
  • 6[5]Rembacken BJ,Snelling AM,Hawkey PM,Chalmers DM,Axon AT.Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis:a randomised trial.Lancet 1999; 354:635-639
  • 7[6]Kruis W,Schutz E,Fric P,Fixa B,Judmaier G,Stolte M.Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.Aliment Pharmacol Ther 1997; 11:853-858
  • 8[7]Prantera C,Scribano ML,Falasco G,Andreoli A,Luzi C.Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease:a randomised controlled trial with Lactobacillus GG.Gut 2002; 51:405-409
  • 9[8]Schultz M,Timmer A,Herfarth HH,Sartor RB,Vanderhoof JA,Rath HC.Lactobacillus GG in inducing and maintaining remission of Crohn's disease.BMC Gastroenterol 2004; 4:5
  • 10[9]Gionchetti P,Rizzello F,Venturi A,Brigidi P,Matteuzzi D,Bazzocchi G,Poggioli G,Miglioli M,Campieri M.Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis:a double-blind,placebo-controlled trial.Gastroenterology 2000; 119:305-309

共引文献6

同被引文献68

引证文献2

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部